CL2021001307A1 - Anticuerpos antiestafilococo y usos de estos - Google Patents
Anticuerpos antiestafilococo y usos de estosInfo
- Publication number
- CL2021001307A1 CL2021001307A1 CL2021001307A CL2021001307A CL2021001307A1 CL 2021001307 A1 CL2021001307 A1 CL 2021001307A1 CL 2021001307 A CL2021001307 A CL 2021001307A CL 2021001307 A CL2021001307 A CL 2021001307A CL 2021001307 A1 CL2021001307 A1 CL 2021001307A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- antigen
- compositions
- binding fragments
- staphylococcal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770608P | 2018-11-21 | 2018-11-21 | |
| US201962822029P | 2019-03-21 | 2019-03-21 | |
| US201962865436P | 2019-06-24 | 2019-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001307A1 true CL2021001307A1 (es) | 2021-11-05 |
Family
ID=68848487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001307A CL2021001307A1 (es) | 2018-11-21 | 2021-05-19 | Anticuerpos antiestafilococo y usos de estos |
| CL2023003084A CL2023003084A1 (es) | 2018-11-21 | 2023-10-17 | Anticuerpos antiestafilococo y usos de estos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003084A CL2023003084A1 (es) | 2018-11-21 | 2023-10-17 | Anticuerpos antiestafilococo y usos de estos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12024556B2 (https=) |
| EP (1) | EP3883963A1 (https=) |
| JP (1) | JP2022512904A (https=) |
| KR (1) | KR20210093856A (https=) |
| CN (1) | CN112867732A (https=) |
| AU (1) | AU2019384790A1 (https=) |
| BR (1) | BR112021005522A2 (https=) |
| CA (1) | CA3110377A1 (https=) |
| CL (2) | CL2021001307A1 (https=) |
| CO (1) | CO2021003752A2 (https=) |
| IL (1) | IL281056A (https=) |
| MA (1) | MA55134A (https=) |
| MX (1) | MX2021005863A (https=) |
| PH (1) | PH12021550538A1 (https=) |
| SG (1) | SG11202102060PA (https=) |
| WO (1) | WO2020106814A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117106077B (zh) * | 2022-04-28 | 2024-07-16 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体 |
| GB202311984D0 (en) * | 2023-08-04 | 2023-09-20 | Petmedix Ltd | Optimised fc molecules |
| CN118580347B (zh) * | 2024-05-13 | 2025-02-07 | 重庆原伦生物科技有限公司 | 一种抗金黄色葡萄球菌蛋白a的单克隆抗体及其应用 |
| CN120943954B (zh) * | 2025-10-20 | 2026-02-06 | 重庆原伦生物科技有限公司 | 抗金黄色葡萄球菌IsdB抗体的制备及其应用 |
| CN120988116B (zh) * | 2025-10-24 | 2025-12-30 | 重庆原伦生物科技有限公司 | 针对金黄色葡萄球菌IsdB的抗体及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20030224000A1 (en) * | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US7488807B2 (en) * | 2006-11-22 | 2009-02-10 | 3M Innovative Properties Company | Antibody with protein A selectivity |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| WO2012122533A2 (en) * | 2011-03-10 | 2012-09-13 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal proteins isda or isdb |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| WO2013096948A1 (en) * | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
| PL3366705T3 (pl) | 2012-09-12 | 2023-09-18 | Genzyme Corporation | FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
| GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| TWI781130B (zh) * | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| CA3076632A1 (en) * | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
-
2019
- 2019-11-20 CA CA3110377A patent/CA3110377A1/en active Pending
- 2019-11-20 US US16/689,593 patent/US12024556B2/en active Active
- 2019-11-20 CN CN201980068132.9A patent/CN112867732A/zh active Pending
- 2019-11-20 BR BR112021005522-3A patent/BR112021005522A2/pt not_active IP Right Cessation
- 2019-11-20 EP EP19818439.2A patent/EP3883963A1/en not_active Withdrawn
- 2019-11-20 KR KR1020217010936A patent/KR20210093856A/ko active Pending
- 2019-11-20 AU AU2019384790A patent/AU2019384790A1/en not_active Abandoned
- 2019-11-20 MA MA055134A patent/MA55134A/fr unknown
- 2019-11-20 WO PCT/US2019/062370 patent/WO2020106814A1/en not_active Ceased
- 2019-11-20 MX MX2021005863A patent/MX2021005863A/es unknown
- 2019-11-20 SG SG11202102060PA patent/SG11202102060PA/en unknown
- 2019-11-20 JP JP2021523954A patent/JP2022512904A/ja active Pending
-
2021
- 2021-02-23 IL IL281056A patent/IL281056A/en unknown
- 2021-03-11 PH PH12021550538A patent/PH12021550538A1/en unknown
- 2021-03-24 CO CONC2021/0003752A patent/CO2021003752A2/es unknown
- 2021-05-19 CL CL2021001307A patent/CL2021001307A1/es unknown
-
2023
- 2023-10-17 CL CL2023003084A patent/CL2023003084A1/es unknown
-
2024
- 2024-05-21 US US18/670,663 patent/US20240301041A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US12024556B2 (en) | 2024-07-02 |
| KR20210093856A (ko) | 2021-07-28 |
| BR112021005522A2 (pt) | 2021-06-29 |
| PH12021550538A1 (en) | 2022-02-21 |
| US20200157193A1 (en) | 2020-05-21 |
| WO2020106814A1 (en) | 2020-05-28 |
| CO2021003752A2 (es) | 2021-04-19 |
| AU2019384790A1 (en) | 2021-03-18 |
| CA3110377A1 (en) | 2020-05-28 |
| CN112867732A (zh) | 2021-05-28 |
| CL2023003084A1 (es) | 2024-04-12 |
| US20240301041A1 (en) | 2024-09-12 |
| IL281056A (en) | 2021-04-29 |
| JP2022512904A (ja) | 2022-02-07 |
| MA55134A (fr) | 2021-09-29 |
| MX2021005863A (es) | 2021-07-16 |
| SG11202102060PA (en) | 2021-03-30 |
| EP3883963A1 (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001307A1 (es) | Anticuerpos antiestafilococo y usos de estos | |
| CL2020003096A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| AR121522A1 (es) | ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19) | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| MX385545B (es) | Anticuerpos humanos para pd-1. | |
| EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
| BR112017027549A2 (pt) | anticorpo para cd40 | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| MX2023011121A (es) | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. | |
| EA202090559A1 (ru) | Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение | |
| MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
| BR112014021477A2 (pt) | anticorpos para metaloproteinase de matriz 9 | |
| EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
| WO2020076789A3 (en) | Combinations of anti-staphylococcus aureus antibodies | |
| BR112021013397A2 (pt) | Anticorpos anti-tigit | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| BR112022020410A2 (pt) | Anticorpos anti-phf-tau e usos dos mesmos | |
| CO2021007882A2 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
| EA201990222A1 (ru) | Антитела к o2 и пути их применения | |
| AR122213A1 (es) | Anticuerpos anti-cd200r1 y métodos de uso de estos | |
| BR112015021964A2 (pt) | Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos | |
| EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения | |
| BR112022014417A2 (pt) | Anticorpos anti-e-selectina, composições e métodos de uso | |
| MX2018004228A (es) | Anticuerpo que se une especificamente a erbb3 y uso de este. |